In their Article in The Lancet Microbe, Bernadette Schurink and colleagues found that multiorgan involvement of COVID-19 is not directly virus induced but mainly due to the pathobiological immune alterations.1 Their outstanding study further outlined the urgent need of crucial biomarkers indicating clinicobiological phase of COVID-19 relevant to key decision making at the bedside of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
We have described three immunogenomic phases (“initial”, “propagating”, “complicating”) of coronavirus (CoV) infections and their corresponding transcripts (ACE2, ANPEP, EGFR, IGF2R, IFN) as potential biomarkers.2, 3 At the “initial” and “propagating” phases of CoV infection, crucial renin-angiotensin system family genes were up-regulated (ACE2, ANPEP) while some others (EGFR, IGF2R) were down-regulated. Antivirals and immunomodulation with immune plasma or intravenous immunoglobulin seem to be appropriate treatments during the first two phases of CoV infections.3 During the “complicating” phase, there is an increase in the expression of some key immune system genes, particularly IFN-family genes.2 Glucocorticoids, monoclonal antibodies, and other immunosuppressive regimens might be most useful during the third “complicating” phase of CoV infections, the phase associated with macrophage activation and exaggerated or disproportionate immune attack.3
Schurink and colleagues disclosed multisystemic COVID-19-associated inflammatory changes in the lungs, heart, kidneys, and brain.1 All of those organs have a local autocrine tissue renin-angiotensin system4 that could be affected by the SARS-CoV-2 ACE2 interactions and their immunoinflammatory pathological outcomes. Therefore, directed renin-angiotensin system modulator medicines, such as soluble ACE2, APN01, angiotensin (1–7), TXA127, and MAS receptor agonists,3, 4, 5 might be considered to be so-called drugs of hope for the pharmacobiological management of the all three stages of CoV infection on the basis of future controlled clinical trials.3
Acknowledgments
I declare no competing interests.
References
- 1.Schurink B, Roos E, Radonic T. Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study. Lancet Microbe. 2020;1:e290–e299. doi: 10.1016/S2666-5247(20)30144-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Turk C, Turk S, Temirci ES, Malkan UY, Haznedaroglu İC. In vitro analysis of the renin–angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus. J Renin Angiotensin Aldosterone Syst. 2020;21 doi: 10.1177/1470320320928872. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Turk C, Turk S, Malkan UY, Haznedaroglu IC. Three critical clinicobiological phases of the human SARS-associated coronavirus infections. Eur Rev Med Pharmacol Sci. 2020;24:8606–8620. doi: 10.26355/eurrev_202008_22660. [DOI] [PubMed] [Google Scholar]
- 4.Ciftciler R, Haznedaroglu IC. Pathobiological Interactions of Local Bone Marrow Renin-Angiotensin System and Central Nervous System in Systemic Arterial Hypertension. Front Endocrinol (Lausanne) 2020;11:425. doi: 10.3389/fendo.2020.00425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ciftciler R, Ciftciler AE, Haznedaroglu IC. Local bone marrow renin-angiotensin system and COVID-19. Int J Hematol Oncol. 2020;30:113–120. [Google Scholar]